Skip to main content
SpringerLink
Log in

Studies on the biological effects of ozone: 5. Evaluation of immunological parameters and tolerability in normal volunteers receiving ambulatory autohaemotherapy

  • Published:
Biotherapy

Abstract

Autohaemotherapy, after a bland treatmentex vivo of blood with ozone, is a fairly unknown medical procedure claimed to have therapeutic value in viral diseases and neoplasms. Having already shown that ozone acts as a mild inducer of cytokines, we have undertaken an investigation in normal rabbits and in normal volunteers aiming to evaluate eventual changes of some cytokine levels in plasma as well as of immunological parameters such as the Mx protein, neopterin,β2-microglobulin and of some acute-phase proteins after single or repeated autohaemotherapy. We have also evaluated the potential development of side-effects. This study is the first one to show that autohaemotherapy can activate an immunological marker in normal subjects without procuring any toxic effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AA:

antiviral activity

β2-M:

β2-microglobulin

BRM:

biological response modifiers

CPD:

citrate-phosphate-dextrose

GM-CSF:

granulocyte-macrophage colony stimulating factor

IFN:

interferon

IL:

interleukin

LPS:

lipopolysaccharide

Np:

neopterin

PBMC:

peripheral blood mononuclear cells

TIL:

tumor-infiltrating lymphocytes

TNFα :

tumor necrosis factor

References

  1. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 1987; 316: 889–97.

    PubMed  Google Scholar 

  2. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New Engl J Med 1987; 316: 898–905.

    PubMed  Google Scholar 

  3. Belldegrun A, Tso CL, Sakata T, Duckett T, Brunda MJ, Barsky SH, Chai J, Kaboo R, Lavey RS, McBride WH, Dekernion JB. Human renal carcinoma line transfected with interleukin-2 and/or interferonα gene(s): implications for live cancer vaccines. J Natl Cancer Institute 1993; 85: 207–16.

    Google Scholar 

  4. Vosika GJ. Clinical immunotherapy trials of bacterial components derived from mycobacteria and nocardia. J Biol Resp Modif 1983; 2: 321–42.

    Google Scholar 

  5. Ribi E, Cantrell JL, Takayama K, Qureshi N, Peterson J, Ribi HO. Lipid A and immunotherapy. Rev Infect Dis 1984; 6: 567–72.

    PubMed  Google Scholar 

  6. Michelson AM, Lacour F, Lacour J. Polyadenylic polyuridylic acid in the cotreatment of cancer. Proc Soc Exp Biol Med 1985; 179: 1–8.

    PubMed  Google Scholar 

  7. Hubbell HR, Pequignot EC, Todd J, Raymond LC, Mayberry SD, Carter WA, Strayer DR. Augmented antitumor effect of combined human natural interferon-alpha and mismatched double-stranded RNA treatment against a human malignant melanoma xenograft. J Biol Resp Modif 1987; 6: 525–36.

    Google Scholar 

  8. Borden EC, Sidky YA, Ertürk E, Wierenga W, Bryan GT. Protection from carcinogen-induced Murine Bladder Carcinoma by interferons and an oral interferon-inducing Pyrimidinone, Bropirimine. Cancer Res 1990; 50: 1071–4.

    PubMed  Google Scholar 

  9. Smee DF, Alaghamandan HA, Cottam HB, Jolley WB, Robins RK. Antiviral Activity of the novel immune modulator 7-THIA-8-Oxoguanosine. J Biol Resp Modif 1990; 9: 24–32.

    Google Scholar 

  10. Lafreniere R, Borkenhagen K, Bryant LD, Ng E, Hayton S. Synergistic actions of Picibanil (OK-432) on recombinant interleukin-2 induction of tumor-infiltrating lymphocyte expansion, cytotoxicity, and phenotypic differentiation. J Biol Resp Modif 1990; 9: 53–60.

    Google Scholar 

  11. Litton GJ, Hong R, Grossberg SE, Vechlekar D, Goodavish CN, Borden EC. Biological and clinical effects of the oral immunomodulator 3,6-Bis(2-piperidinoethoxy) acridine trihydrochloride in patients with malignancy. J Biol Resp Modif 1990; 9: 61–70.

    Google Scholar 

  12. Paulesu L, Bocci V, Pessina GP, Nicoletti C, Boccanera M, Cassone A. Interferon induction in rabbits after intraduodenal administration of a phosphorylated glucomannan-protein fraction of the cell wall of Candida albicans. Immunol Lett 1991; 27: 231–6.

    PubMed  Google Scholar 

  13. Wehrli F. Zur Verhütung unerwünschter nebenwirkungen bei blutranfusionen. Transactions of the VI congress of the European Society of Haematology 1957; 1: 318.

    Google Scholar 

  14. Matassi R, Bassi P, D'Angelo F, Franchina A, Sbrascini S. Ozone as therapy in herpes simplex and herpes zoster diseases. In Medical Applications of Ozone edited by LaRaus J, Norwalk: International Ozone Association 1985; pp. 134–7.

  15. Konrad H. Ozone vs hepatitis and herpes the choice. In Medical Applications of Ozone edited by LaRaus J, Norwalk: International Ozone Association 1985; pp. 140–6.

  16. Bocci, V. Ozonization of blood for the therapy of viral diseases and immunodeficiencies. A hypothesis. Medical Hypotheses 1992; 39: 30–4.

    PubMed  Google Scholar 

  17. Novogrodsky A, Stenzel KH, Rubin AL. Stimulation of human peripheral blood lymphocytes by periodate, galactose oxidase, soybean agglutinin, and peanut agglutinin: differential effects of adherent cells. J Immunol 1977; 118: 852–7.

    PubMed  Google Scholar 

  18. Antonelli G, Blalock JE, Dianzani F. Generation of a soluble IFNγ-inducer by oxidation of galactose residues on macrophages. Cell Immunol 1985; 94:440–6.

    PubMed  Google Scholar 

  19. Bocci V, Paulesu L. Studies on the biological effects of ozone 1. Induction of interferon gamma on human leucocytes. Haematologica 1990; 75: 510–5.

    PubMed  Google Scholar 

  20. Paulesu L, Luzzi E, Bocci V. Studies on the biological effects of ozone 2. Induction of tumor necrosis factor (TNF-α) on human leucocytes. Lymphokine Cytokine Res 1991; 10:409–12.

    PubMed  Google Scholar 

  21. Bocci V, Luzzi E, Corradeschi F, Paulesu L, Di Stefano A. Studies on the biological effects of ozone: 3. An attempt to define conditions for optimal induction of cytokines. Lymphokine Cytokine Res. 1993; 12: 121–6.

    PubMed  Google Scholar 

  22. Lippman M. Health effects of ozone, a critical review. J Am Air Pollut Control Assoc 1989; 39: 672–95.

    Google Scholar 

  23. Armstrong, JA. Cytopathic effect inhibition assay for interferon: microculture plate assay. In: Methods in enzymology, edited by Pestka, S. New York: Academic Press, 1981, pp. 381–7.

    Google Scholar 

  24. Ruff, MR, Gifford, GE. Tumor necrosis factor. In: Lymphokines, edited by Pick, E. New York: Academic Press, 1981, pp. 235–41.

    Google Scholar 

  25. Towbin H, Schmitz A, Jakschies D, Von Wussow P, Horisberger MA. A whole blood immunoassay for the interferon-inducible human Mx protein. J Interf Res 1992; 12: 67–74.

    Google Scholar 

  26. Liberati AM, Horisberger MA, Palmisano L, Astolfi S, Nastari A, Mechati S, Villa A, Mancini S, Arzano S, Grignani F. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-β. J Interf Res 1992; 12: 329–36.

    Google Scholar 

  27. Jacobs M. Th-Untersuchung uber zwischerfdlle und typische complikationen in der ozon. Sauerstoff Therapie. Ozonachrichten 1986; 1–5.

  28. Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investig 1992; 70: 539–44.

    PubMed  Google Scholar 

  29. Bocci, V. Metabolism of protein anticancer agents. Pharm. Ther. 1987; 34: 1–49.

    Google Scholar 

  30. Bocci, V. Interleukins. Clinical pharmacokinetics and practical implications. Clin. Pharmacokinet 1991; 21: 274–84.

    PubMed  Google Scholar 

  31. Bocci, V. Roles of interferon produced in physiological conditions. A speculative review. Immunology 1988; 64: 1–9.

    PubMed  Google Scholar 

  32. Bocci, V. Evaluation of routes of administration of interferon in cancer: a review and a proposal. Cancer Drug Del 1984; 1: 337–51.

    Google Scholar 

  33. Bocci, V. Immunomodulators as local hormones: new insights regarding their clinical utilization. J Biol Resp Modif 1985; 4: 340–52.

    Google Scholar 

  34. Bocci, V. Tumor therapy with biological response modifiers. Why is progress slow? EOS-J. Immunol Immunopharmacol 1990; 10: 79–82.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, Institute of General Physiology, Via Laterina 8, 53100, Siena, Italy

    Velio Bocci

  2. Faculty of Pharmacy, Biological Sciences, Institute of General Physiology, University of Siena, Italy

    Fausto Corradeschi & Luana Paulesu

Authors
  1. Velio Bocci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Enrico Luzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fausto Corradeschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luana Paulesu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bocci, V., Luzzi, E., Corradeschi, F. et al. Studies on the biological effects of ozone: 5. Evaluation of immunological parameters and tolerability in normal volunteers receiving ambulatory autohaemotherapy. Biotherapy 7, 83–90 (1993). https://doi.org/10.1007/BF01877731

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01877731

Key words

Search

Navigation